725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Sampriti Banerjee, Rafael Grochot, R. Shinde, Julianne Lima, Matthew Krebs, Rabik Rahman, Martin Little, Nina Tunariu, A. Curcean, H. Badham, M. Mahmud, A. Turner, Mahesh Parmar, Christina Yap, Anna Minchom, J. Lopez, J. Bono, Udoyan Banerji

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S728
JournalAnnals of Oncology
Volume32
DOIs
Publication statusPublished - 1 Sept 2021

Cite this